Comparative analysis on adverse event following immunization after routine immunization and supplementary immunization activities of measles-containing vaccine in Hebei Province, 2010-2018
WANG Ya-fei, XU Xiao-meng, WANG Jing-hui, DU Hui, WANG Yi-han, CUI Shi-heng, WANG Li-na, ZHANG Fu-bin, SUN Li
Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei 050021, China
Abstract：Objective To understand the differences in the surveillance data regarding adverse event following immunization (AEFI) between routine immunization and supplementary immunization activities of measles-containing vaccine (MCV) in Hebei Province during 2010-2018, and to provide a scientific basis for optimizing MCV supplementary immunization strategy. Methods We collected the data about AEFI cases, routine vaccination and supplementary immunization of MCV specially-reported by each city in Henan Province during 2010-2018 through the National Immunization Program Information Management System. Descriptive epidemiological method was used to statistically analyze the characteristics of AEFI surveillance after routine immunization and supplementary immunization of MCV. Results A total of 9,352 AEFI cases after routine immunization of MCV and 2,590 AEFI cases after supplementary immunization of MCV were reported in Hebei Province from 2010 to 2018. The reported incidence rates of total AEFI, common adverse reactions and rare adverse reactions after routine immunization were 47.81/100,000 doses, 45.31/100,000 doses and 2.32/100,000 doses, respectively, while the above-mentioned incidence rates after supplementary immunization were 64.40/100,000 doses, 54.03/100,000 doses and 9.08/100,000 doses, respectively. Among severe adverse reactions, the reported incidence rates of febrile convulsions, thrombocytopenia and acute severe anaphylaxis after routine immunization were 0.07/100,000 doses, 0.16/100,000 doses and 0.02/100,000 doses, respectively, whereas the above-mentioned incidence rates after supplementary immunization were 0.35/100,000 doses, 0.07/100,000 doses and 0.15/100,000 doses, respectively. Conclusion AEFI after routine immunization and supplementary immunization of MCV in Hebei Province during 2010-2018 was mainly common vaccine reactions, and severe reactions were extremely rare. MCV in Hebei Province is safe.
王亚菲, 许晓萌, 王晶辉, 杜慧, 王易寒, 崔世恒, 王丽娜, 张富斌, 孙丽. 2010—2018年河北省含麻疹成分疫苗常规免疫和补充免疫疑似预防接种异常反应对比分析[J]. 实用预防医学, 2022, 29(7): 818-821.
WANG Ya-fei, XU Xiao-meng, WANG Jing-hui, DU Hui, WANG Yi-han, CUI Shi-heng, WANG Li-na, ZHANG Fu-bin, SUN Li. Comparative analysis on adverse event following immunization after routine immunization and supplementary immunization activities of measles-containing vaccine in Hebei Province, 2010-2018. , 2022, 29(7): 818-821.
[1] Moten M, Phillips A, Saliba V, et al.Measles: is it still a threat?[J].Brit J Gen Pract,2018, 68(674):404-405. [2] Orenstein WA,Cairns L,Hinman A,et al. Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: background and summary[J]. Vaccine,2018,36 (Suppl 1):A35-42. [3] 王华庆,安志杰,尹遵栋.国家免疫规划七种针对传染病70年防控成就回顾[J].中国疫苗免疫, 2019, 25(4):359-367. [4] 苏琪茹,郝利新,马超,等.中国2015—2016年麻疹流行病学特征分析[J].中国疫苗和免疫, 2018, 24(2):146-151. [5] 马超,苏琪茹,郝利新,等.中国2017—2018年麻疹流行病学特征[J].中国疫苗和免疫, 2020, 26(1):5-8, 41. [6] 刘韬,马莉,袁欢喜,等.怀化市D8基因型麻疹暴发疫情的危险因素分析[J].实用预防医学, 2021, 28(9):1117-1119. [7] 国家卫生和计划生育委员会.预防接种工作规范(2016年版)[Z].2016-12-06. [8] Patel MK,Dumolard L,Nedelec Y,et al.Progress toward regional measles elimination-worldwide, 2000-2018[J].MMWR, 2019, 68(48):1105-1111. [9] World Health Organization.Planning and implementing high-quality supplementary immunization activities for injectable vaccines: using an example of measles and rubella vaccines[R].Geneva: WHO, 2020:1-199. [10] Meng FY,Sun Y,Shen YG,et al.Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China[J].PLoS One, 2017, 12(2):e0172108. [11] 史金晶,唐智敏,余文周.疫苗犹豫现状及其应对措施[J].中国疫苗和免疫, 2019, 25(4):481-486. [12] Black S, Eskola J, Siegrist CA, et al.Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines[J].Lancet, 2009, 374(9707):2115-2122. [13] 曾雪霞,陈少明,莫少雄,等.海南省2010年麻疹疫苗强化免疫活动AEFI监测与处置[J].中国热带医学, 2012,12(5):552-555. [14] 白庆瑞,杨建萍,陆菁,等.上海市2010年强化免疫活动中麻疹减毒活疫苗和麻疹-流行性腮腺炎-风疹联合减毒活疫苗的安全性观察[J].中国疫苗和免疫, 2011, 17(6):526-530, 544. [15] 丛艳丽,孙丽,崔世恒,等.河北省2016年麻疹流行特征及控制策略分析[J].实用预防医学, 2019, 26(10):1245-1247. [16] 丛艳丽,孙丽,张富斌,等.2015年河北省麻疹流行特征及消除麻疹策略[J].职业与健康, 2017, 33(13):1853-1855. [17] 中华人民共和国卫生部办公厅.2010 年全国麻疹疫苗强化免疫活动方案[Z].2010-07-26. [18] 黄芳,张世英.深圳市2009—2013年含麻疹成分疫苗疑似预防接种异常反应监测分析[J].微生物学免疫学进展, 2015, 43(1):35-39. [19] 梁雪枫,安婧,唐宇.国产含麻类疫苗多剂次接种的安全性评价[J].中国初级卫生保健, 2019, 33(4):65-66. [20] 李克莉,张丽娜,叶家楷,等.中国2017年疑似预防接种异常反应监测[J].中国疫苗和免疫, 2020,26(1):9-18. [21] World Health Organization, Regional Office for the Western Pacific.Immunization safety surveillance: guidelines for immunization programme managers on surveillance of adverse events following immunization.3rd ed[R].Manila: WHO Regional Office for the Western Pacific, 2015:1-104. [22] World Health Organization.Global manual on surveillance of adverse events following immunization, 2016 update[R].Geneva: WHO, 2016:1-109.
2022, Vol. 29 
